Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

Virus-neutralizing antibodies are a severe obstacle in oncolytic virotherapy. Here, we present a strategy to convert this unfavorable immune response into an anticancer immunotherapy via molecular retargeting. Application of a bifunctional adapter harboring a tumor-specific ligand and the adenovirus...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemann, Julia, Woller, Norman, Brooks, Jennifer, Fleischmann-Mundt, Bettina, Martin, Nikolas T., Kloos, Arnold, Knocke, Sarah, Ernst, Amanda M., Manns, Michael P., Kubicka, Stefan, Wirth, Thomas C., Gerardy-Schahn, Rita, Kühnel, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642145/
https://www.ncbi.nlm.nih.gov/pubmed/31324774
http://dx.doi.org/10.1038/s41467-019-11137-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642145/
https://www.ncbi.nlm.nih.gov/pubmed/31324774
http://dx.doi.org/10.1038/s41467-019-11137-5

Ejemplares similares